A Post Hoc Analysis of Statin Use in Tolvaptan Autosomal Dominant Polycystic Kidney Disease Pivotal Trials

od Shoaf, Susan E., Ouyang, John, Sergeyeva, Olga, Estilo, Alvin, Li, Hui, Leung, Deborah
Wydane w Clin J Am Soc Nephrol (2020)

The NOCTURNE Randomized Trial Comparing 2 Tolvaptan Formulations

od Perrone, Ronald D., Chapman, Arlene B., Oberdhan, Dorothee, Czerwiec, Frank S., Sergeyeva, Olga, Ouyang, John, Shoaf, Susan E.
Wydane w Kidney Int Rep (2020)

A Randomized Trial of Modified-Release Versus Immediate-Release Tolvaptan in ADPKD

od Perrone, Ronald D., Chapman, Arlene B., Oberdhan, Dorothee, Czerwiec, Frank S., Sergeyeva, Olga, Ouyang, John, Shoaf, Susan E.
Wydane w Kidney Int Rep (2020)

Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease

od Torres, Vicente E., Devuyst, Olivier, Chapman, Arlene B., Gansevoort, Ron T., Perrone, Ronald D., Ouyang, John, Blais, Jaime D., Czerwiec, Frank S., Sergeyeva, Olga
Wydane w Am J Nephrol (2017)

Multicenter Study of Long-Term Safety of Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease

od Torres, Vicente E., Chapman, Arlene B., Devuyst, Olivier, Gansevoort, Ron T., Perrone, Ronald D., Lee, Jennifer, Hoke, Molly E., Estilo, Alvin, Sergeyeva, Olga
Wydane w Clin J Am Soc Nephrol (2021)